Table 7.

Acute respiratory symptoms observed in the post-intervention period.

	Placebo (n = 25)	LF (n = 16)	P
FEVER
Prevalence, n (%)	7 (28.0)	3 (18.8)	0.712
Fever, days	0 (0, 1)	0 (0, 0)	0.682
Duration, days/episode	1 (1, 2)	1.5 (1, –)	1.000
NASAL SECRETION/CONGESTION
Prevalence, n (%)	24 (96.0)	16 (100)	1.000
Nasal secretion/congestion, days	6 (2, 8)	2 (1.25, 4.75)	0.101
Duration, days/episode	5 (1.63, 7.75)	2 (1, 4.75)	0.113
COUGH/SPUTUM
Prevalence, n (%)	19 (76.0)	11 (68.8)	0.723
Cough/sputum, days	2 (0.5, 6)	1.5 (0, 4.75)	0.361
Duration, days/episode	4 (2, 5)	3 (1, 5)	0.525
FATIGUE
Prevalence, n (%)	9 (36.0)	5 (31.3)	1.000
Fatigue, days	0 (0, 1)	0 (0, 1)	0.741
Duration, days/episode	1 (1, 3)	1 (1, 2.5)	0.898
OTHERS
Prevalence, n (%)	0 (0)	2 (12.5)	0.146
Others, days	0 (0, 0)	0 (0, 0)	0.517
Duration, days/episode	– (–, –)	1.5 (1, –)	–

Prevalence is defined as the number of participants who experienced more than one symptom.

Symptom days is defined as the cumulative number of symptomatic days.

Duration is defined as the mean of consecutive days per episode.

Otitis media and eye discharge associated with other respiratory symptoms.